申请人:Constance Therapeutics, Inc.
公开号:US10238745B2
公开(公告)日:2019-03-26
A cannabinoid composition having an excipient including α-tocopherol and at least one isolated cannabinoid having a purity of greater than 80%. The α-tocopherol inhibits oxidation, regulates viscosity of the composition, and improves bioavailability of the cannabinoid. The composition includes a carrier oil mixed with the excipient and cannabinoid. In one embodiment, the at least one cannabinoid is an isolated cannabinoid having a greater than 80% purity, and preferably greater than 90% purity. The at least one cannabinoid is selected from the group consisting of phytocannabinoids, endocannabinoids, synthetic cannabinoids, and combinations thereof. The cannabinoid may be derived from plants other than cannabis sativa, or synthesized from fungi, bacteria, yeast or other synthetic method. Preferably the α-tocopherol comprises at least 10% w/w of the composition.
一种大麻素组合物,其赋形剂包括α-生育酚和至少一种纯度大于 80% 的分离大麻素。α-生育酚可抑制氧化,调节组合物的粘度,提高大麻素的生物利用度。组合物包括与赋形剂和大麻素混合的载体油。在一个实施方案中,至少一种大麻素是分离出来的大麻素,纯度大于 80%,最好大于 90%。至少一种大麻素选自植物大麻素、内源性大麻素、合成大麻素及其组合组成的组。大麻素可以从大麻以外的植物中提取,也可以从真菌、细菌、酵母或其他合成方法中合成。α-生育酚最好至少占组合物重量的 10%。